December 17, 2025 10:06 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns | Market update: Sensex tumbles 120 points, Nifty below 25,850 at closing bell | ‘Won’t apologise’: Prithviraj Chavan stands firm on controversial Operation Sindoor remark despite backlash | India summons Bangladesh High Commissioner after provocative 'seven sisters' remark | Amazon eyes $10 billion investment in OpenAI — a gamechanger for AI industry! | Goa nightclub fire horror: Luthra brothers brought back to India from Thailand, arrested | Messi chaos costs minister his job: Aroop Biswas resigns after Salt Lake Stadium fiasco | Bengal SIR draft list out: Around 58 lakh voters’ names dropped | Relief for Sonia, Rahul Gandhi as Delhi court refuses to act on ED chargesheet in National Herald case | Centre moves to replace MGNREGA with 'G Ram G', sets stage for winter session showdown

Aurobindo Pharma receives USFDA approval for drug related to moderate dementia

| | Mar 29, 2016, at 08:16 pm
#Aurobindo Pharma receives USFDA # US Food & Drug Administration
Hyderabad/Mumbai, Mar 29 (IBNS) Aurobindo Pharma Limited, which manufactures generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.
This product is expected to be launched in the first quarter of fiscal year 2016-17.
 
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation, said the company.
 
Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease. 
 
The approved product has an estimated market size of US$ 26.7 million for the twelve months ending January 2016 according to IMS.
 
This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing oral non-antibiotic products. 
 
Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Images
Nirmala Sitharaman presents Budget 2025
Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:41 pm
Veedol signs former Indian skipper Sourav Ganguly as brand ambassador
Veedol signs former Indian skipper Sourav Ganguly as brand ambassador Jun 29, 2024, at 06:38 am
In Images: Glimpses from Bengali film Fatafati's premiere
In Images: Glimpses from Bengali film Fatafati's premiere May 13, 2023, at 08:39 pm
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm